This prospectively designed study was conducted to compare a fertile and a subfertile population so as to define normal values for different semen parameters. Semen analyses were performed according to the World Health Organization (WHO) guidelines, except for sperm morphology (strict criteria). In the fertile population (n = 144), all patients had recently achieved pregnancy, within 12 months of unprotected coitus. As subfertile controls we examined semen samples from 143 consecutive men attending our infertility clinic during the same study period. Couples with tubal factor infertility and/or ovulatory disorders were excluded from our study. Using receiver operating characteristic (ROC) curve analysis we determined the diagnostic potential and cut-off values for single and combined sperm parameters. Sperm morphology scored best, with a value of 78% (area under the ROC curve). Summary statistics showed a shift towards abnormality for most semen parameters in the subfertile population. Using the 10th percentile of the fertile population as the cut-off value, the following results were obtained: 14.3 x 10(6)/ml for sperm concentration, 28% for progressive motility and 5% for sperm morphology. Using ROC analysis, cut-off values were 34 x 10(6)/ml, 45% and 10% respectively. Cut-off values for normality were different from those described in the WHO guidelines. Routine bacterial and non-bacterial cultures turned out to be of little prognostic value.
Outcome of treatment according to a fixed protocol with a mixture of PDS and NACT-IDS was similar to results from large databases. We hypothesize that comparison of a specific strategy may yield more useful results than awaiting the perfect randomized trial.
Despite premature trial closure, our data provided valuable insights. Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances. Safe and effective interventions are needed to alleviate sexual dysfunction.
Background: The switch to adjuvant anastrozole/exemestane after 2-3 years of tamoxifen improves breast cancer outcome. Prior to this knowledge, we designed a multicentre randomised placebo-controlled study, to evaluate uterine and quality of life (QoL) issues comparing those switching to anastrozole and those continuing on tamoxifen in patients with a thickened endometrium after 2-3 years of tamoxifen treatment. The study was prematurely closed when anastrozole/exemestane became reimbursed by our health authorities following publication of a survival benefit from the adjuvant switch strategy in this setting. We here report on all randomized patients.Patients and Methods: Patients were postmenopausal, asymptomatic with a double endometrial thickness (DET) on transvaginal ultrasound (TVUS) of more than 7 mm. They were randomized between 20mg tamoxifen and 1mg anastrozole during the rest of 5 years of endocrine treatment; tablets were unrecognizable for drug assignment. The study aimed at investigating the TVUS changes with a measurement at baseline, at year 1 and when completing the endocrine therapy unless there were QoL issues, progression or vaginal bleeding. The primary study-endpoint was the change in DET and uterine volume (UV). Secondary endpoints were differences in the occurrence of menopausal symptoms between groups. Longitudinal fixed-effects regression analysis methods were used to evaluate uterine changes and QoL scores over time. Age and BMI were used as covariates.Results: The study randomized 72 subjects (37 anastrozole and 35 tamoxifen) from 5 institutions. Mean age (range) was 60 years (43 – 77 years); demographics were comparable but patients randomized to anastrozole were more likely lymph node positive. Subjects on anastrozole had a significant decrease in mean change in DET and UV already after 1 year. Both primary endpoints did not change over time when continuing tamoxifen but between-group differences were significant (p-values < 0.001). The covariates did not influence the effect of medication. Eleven patients withdrew from the study (7 on anastrozole; 4 on tamoxifen, ns); 2 had disease progression (both on anastrozole), 1 (on tamoxifen) developed a hematologic cancer, 7 stopped because of side effects (5 on anastrozole and 2 on tamoxifen) and arthralgia being most frequently reported for early stopping (4 anastrozole and 1 tamoxifen). AEs/SAEs were observed in 54% and 11% of patients on anastrozole and in 51% and 17% of patients on tamoxifen (ns). Regarding QoL, vaginal dryness increased for patients on anastrozole but not for patients on tamoxifen (p=0.008). No different evolution of arthralgia between both groups is suggested, even though more anatrozole patients withdrew due to arthralgia problems. Vaginal bleeding was reported in 5 (3 on tamoxifen and 2 on anastrozole).Conclusion: Although the study was prematurely stopped, we were able to show a strong decrease in DET and UV in asymptomatic postmenopausal tamoxifen users with a thickened endometrium after 2-3 years of tamoxifen who change to anastrozole. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4093.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.